|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 15, 2012 ) New York, NY -- VFC's Stock House identifies various healthcare companies making mid-week news.
Although the broad markets were trending lower to start the new trading week as European economic data continued to look weak, there were - as always - some exciting and encouraging stories making headlines in the markets that are worth investor interest.
While the current market dip has been modest thus far and has not caused any widespread panic that would lead to a mass exodus of investors, any decline usually offers investors the opportunity to 'average down' on their investments and pick up a few shares of companies that they are following for sometimes 'discounted' prices.
The healthcare sector in particular - given its speculative nature - is prone to more dramatic moves than most others and that volatility creates an environment that traders love. With that said, the 'buy and hold' crowd could also do quite well, if they've got the stomach to ride out the volatility and wait for the potential to play out.
With those thoughts in mind, here's a few still-developing companies that are attracting their share of interest in the healthcare sector worth keeping an eye on...
NeoStem, Inc. (NBS): Overall, it's been a relatively good year for companies in the stem cell sector. Many, like NeoStem, are looking to position themselves to play a key role in what is arguably being considered as the future of medicine. With a solid portfolio of intellectual property, a strong pipeline of clinical and pre-clinical treatments, and with encouraging progress noted thus far in development, NeoStem is boasts the potential to become a major 'next-generation' type of player in treatment using cell therapies.
Full watch list available by visiting: http://vfcsstockhouse.com/blog/article/-mid-week-healthcare-stock-watch-neostem-s-potential-trial-news-for-synergy-and-other-hot-stocks-to-watch
Pharmacyclics (PCYC): When discussing potential 'buy and hold' stories, it's hard to ignore the mother of all recent 'buy and hold' successes. Just a few years ago - well, four to be exact - shares of Pharmacyclics were trading for a dollar following the failure of its late-stage drug candidate, Xcytrin. Shares quickly rebounded, however, to over two bucks, then three, then fell again to below two. At the time, investors such as myself considered that volatility as heavenly trading territory and were happy with the profits provided by the share price fluctuations.
Synergy Pharmaceuticals (SGYP): Synergy Pharmaceuticals issued milestone news this week by announcing the completion of enrollment for its Phase IIb/III clinical trial measuring the effectiveness of Plecanatide in treating chronic idiopathic constipation (CIC). While some investors may brush off such developments as 'insignificant,' this is key news for Synergy, and such developments should not be ignored in relation to any still-developing company.
MRI Interventions (MRIC): MRIC also reported milestone news this week by announcing in conjunction with Brainlab that the company's ClearPoint system "is being used in a groundbreaking clinical trial for the treatment of pediatric brain cancer."
In conjunction with this announcement, it was revealed that the first procedure had already taken place and the early results were encouraging. A team of professionals gathered at the Memorial Sloan Kettering Cancer Center and "used the ClearPoint System in the delivery of a cancer-fighting agent into the tumor of a pediatric patient while viewing three-dimensional MRI images of the delivery in real-time throughout the procedure."
For full list of this week's hot stocks to watch visit: http://vfcsstockhouse.com/blog/article/-weekly-stock-watch-week-of-13-august-amrn-mric-sppi-ssh-imsc-bsx-alth-si-cpst-ttnp-cvm
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Originally published at: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
